FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia
-- Approval provides patients with schizophrenia the ability to access the
efficacy and safety profile of oral aripiprazole in a once-monthly
formulation
-- Relapse prevention is an important consideration in the treatment of
patients with schizophrenia; Abilify Maintena(TM) met the phase III
clinical trial primary endpoint of significantly delaying time to relapse
-- Abilify Maintena will be the first commercialized product from the global
alliance be (Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - February 28, 2013 Category: Pharmaceuticals Source Type: news
DGAP-Adhoc: FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia
H. Lundbeck A/S
01.03.2013 00:01
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
-- Approval provides patients with schizophrenia the ability to access the
efficacy and safety profile of oral aripiprazole in a once-monthly
formulation
-- Relapse prevention is an important consideration in the tr (Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - February 28, 2013 Category: Pharmaceuticals Source Type: news
Abilify (aripiprazole) tablets, orodispersible tablets and oral solution - Otsuka and Bristol-Myers Squibb - revised SPC
Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates > SPC Changes
As a result of the new paediatric indication, section 1 has been updated to include an inverted black triangle with an asterisk (*) which signifies that:
* Intensive monitoring is requested only when used for the recently-licensed indication extension to paediatric patients.
Section 4.1 Therapeutic indications now includes additional/new indications for use as below:
ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar 1 Disorder in adolescents aged ...
Source: NeLM - Mental Health - February 28, 2013 Category: Psychiatry Source Type: news
Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
Abilify Overtakes Nexium as the Top Drug by Sales
NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Drugs.com, the leading online
clinical drug resource, today released fourth quarter 2012 U.S.
prescription sales data for the top 100 drugs.
At the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2013 Category: Pharmaceuticals Source Type: news
Abilify® (aripiprazole) 7.5mg/mL solution for injection (intramuscular) - Revised SPC
Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates > SPC Changes
Section 4.4 of the SPC has also been updated to include reports from post-marketing data of pathological gambling. Patients with a prior history of pathological gambling may be at increased risk and should be monitored carefully.
Section 4.8 of the SPC has also been updated to include the following adverse reactions - psychiatric disorders, agitation, nervousness, pathological gambling, suicide attempt, suicidal ideation and completed suicide.
Please see SPC link for full prescribing information...
Source: NeLM - Mental Health - February 12, 2013 Category: Psychiatry Source Type: news
Aripiprazole (ABILIFY®) Approved For The Treatment Of Moderate To Severe Manic Episodes In Bipolar I Disorder In Adolescents
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older. � This will be the first centrally approved indication for the treatment of moderate to severe manic episodes in Bipolar I Disorder in this age group in Europe... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 8, 2013 Category: Consumer Health News Tags: Bipolar Source Type: news
Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs: Abilify Overtakes Nexium as the Top Drug by Sales
NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released fourth quarter 2012 U.S. prescription sales data for the top 100 drugs.
At the close of 2012, Otsuka’s antipsychotic Abilify overtakes... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 7, 2013 Category: Pharmaceuticals Source Type: news
Safely Prescribing Antipsychotic Medications
The use of antipsychotic medications has increased substantially over the last decade. Decisions about whether to prescribe them for particular patients should involve doctors, patients, and, when appropriate, family members. read more (Source: Psychology Today Anxiety Center)
Source: Psychology Today Anxiety Center - February 5, 2013 Category: Psychiatry & Psychology Authors: Eugene Rubin, M.D., Ph.D. Tags: Anxiety Depression Neuroscience Psychiatry antipsychotic medications anxiety disorders aripiprazole chlorpromazine delusions eating disorders hallucinations haloperidol hearing voices olanzapine personality disorders psychiat Source Type: news
Weight Gain on Abilify
Question: "Hello everyone, I'm wondering if anyone has information or experience with weight gain on Abilify? I take a relatively low dose (5 mg) and have been putting on weight within the past few years. I know there are 10,000 reasons why someone can put on weight, but we are trying to rule out medical reasons before I put my nose to the grindstone in effort." - - curlysue41382...Read Full Post (Source: About.com Depression)
Source: About.com Depression - January 21, 2013 Category: Psychiatry Source Type: news
